A clinical trial conducted by investigators at the University of Colorado Boulder has shown that MitoQ, our world-first cellular health innovation, decreases free radical production by mitochondria, and significantly supports arterial function in older adults and therefore the health of the arteries.
In the clinical trial it was validated that:
- MitoQ greatly improved the ability of arteries to dilate (by 42%)
- MitoQ significantly supports the health of aorta
- MitoQ significantly fights oxidative Stress
In previous pre-clinical non-human work, investigators at the University of Colorado Boulder had shown that four weeks of MitoQ treatment improved age-related declines in the ability of arteries to dilate. In a separate study, the same investigators also showed that four weeks of MitoQ treatment helped to support arterial health.
Building on these impressive preliminary results, the investigators at the University of Colorado Boulder have now completed the first human clinical trial investigating the effects of MitoQ on arterial function. The results of this landmark study show that after six weeks of treatment in a group of men and women aged 60-79, MitoQ significantly improved the ability of arteries to dilate by 42%, supporting arterial health. Further echoing their initial study results, the team also found that MitoQ significantly supports arterial flexibility and significantly reduces oxidative stress.
Strikingly, the size of the improvement in arterial dilation after only six weeks was larger than that typically achieved from three months of caloric restriction-based weight loss, and almost as large as that seen from three months of regular aerobic exercise (approximately 30% and 50% respectively). As many middle-aged and older adults do not, or are unable to, meet recommended healthy lifestyle guidelines, MitoQ represents a very promising complementary strategy for maintaining healthy flexible arteries.
The study authors noted the results demonstrated that reducing oxidative stress is a novel and effective way to support vascular function and warranted further larger-scale studies examining MitoQ in clinical conditions of aging.
“In the broadest terms, our results provide initial support for the idea that MitoQ, and potentially other mitochondria-targeted antioxidants, may be an effective treatment for improving vascular function,” write the research team, which was headed up by Matthew Rossman, PhD, a postdoctoral researcher in the University of Colorado's department of integrative physiology.
As a company dedicated to helping people live healthy, energized lives, we are excited to see the results of this groundbreaking study, and to find that the benefits of MitoQ observed in the clinical research setting are consistent with what customers and doctors have been reporting for years. We look forward to further clinical trials in this area in the future.